Cytokinetics (CYTK) Common Equity (2010 - 2026)

Cytokinetics (CYTK) has reported Common Equity for 17 consecutive years, with -$826.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 210.26% year-over-year to -$826.6 million; the TTM figure through Mar 2026 stood at -$826.6 million (down 210.26% YoY), while the FY2025 annual figure was -$659.6 million, down 387.27% from the prior year.
• Common Equity eased to -$826.6 million in Q1 2026 per CYTK's latest filing, from -$659.6 million in the prior quarter.
• Across five years, Common Equity topped out at $116.3 million in Q1 2022 and bottomed at -$826.6 million in Q1 2026.
• Historically, Common Equity has averaged -$256.6 million across 5 years, with a median of -$266.4 million in 2025.
• Annual changes were most pronounced in 2022 — Common Equity soared 575.69% — and 2025, when it plunged 3646.12%.
• Cytokinetics' Common Equity stood at -$107.9 million in 2022, then plunged by 258.04% to -$386.3 million in 2023, then soared by 64.96% to -$135.4 million in 2024, then sank by 387.27% to -$659.6 million in 2025, then declined by 25.31% to -$826.6 million in 2026.
• Business Quant data shows CYTK's Common Equity at -$826.6 million in Q1 2026, -$659.6 million in Q4 2025, and -$521.1 million in Q3 2025.